MedTrace Logo

Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Cancer

NCT05746429 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-02-04

Study results available
· View outcomes & findings →

Summary

This is a prospective study that will conduct a series of focus groups with non-Hispanic Black and Hispanic childhood cancer survivors to obtain their input on culturally adapting a mobile CBT program for chronic pain and tDCS procedures. Once this adaptation process is completed, the investigators will conduct a feasibility trial with non-Hispanic Black, Hispanic and non-Hispanic White survivors of childhood cancer with chronic pain. The feasibility study will assign eligible participants to either culturally adapted mobile CBT + active tDCS to the dorsolateral prefrontal cortex or culturally adapted mobile CBT + sham tDCS. We anticipate approximately 60 participants for the focus groups and approximately 30 participants for the feasibility study for a total of about 90 participants.

Conditions

  • Bone Sarcoma
  • Childhood Cancer

Interventions

BEHAVIORAL

Cognitive Behavior Therapy

Receive mobile CBT

DEVICE

Transcranial Direct Current Stimulation

Undergo active tDCS

DRUG

Placebo Administration

Undergo sham tDCS

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Interview

Attend virtual meetings and focus groups

Sponsors & Collaborators

Principal Investigators

  • Tara Brinkman, PhD · St. Jude Children's Research Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-04-06
Primary Completion
2024-10-29
Completion
2024-10-29
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05746429 on ClinicalTrials.gov